Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657583 | 1.00 | CTSK (0.34) | CTSKCTSSHDAC6AAK1MMP13 | |
| SCHEMBL52414 | 0.83 | CTSK (0.33) | CTSKHDAC6AAK1HDAC1HDAC2 | |
| SCHEMBL52415 | 0.83 | CTSK (0.33) | CTSKHDAC6AAK1HDAC1HDAC2 | |
| SCHEMBL17297221 | 0.79 | HCAR2 (0.35) | HDAC6HDAC1HDAC2 | |
| SCHEMBL20031069 | 0.78 | CTSK (0.35) | CTSKHDAC6AAK1MMP13HDAC1 | |
| SCHEMBL5565242 | 0.77 | CTSS (0.35) | CTSKCTSSHDAC6AAK1MMP13 | |
| SCHEMBL5565245 | 0.77 | CTSS (0.35) | CTSKCTSSHDAC6AAK1MMP13 | |
| SCHEMBL5559416 | 0.75 | CTSK (0.34) | CTSKHDAC6AAK1MMP13HDAC1 | |
| SCHEMBL4299159 | 0.75 | CTSK (0.34) | CTSKHDAC6AAK1MMP13HDAC1 | |
| SCHEMBL8274243 | 0.75 | CTSK (0.34) | CTSKHDAC6AAK1MMP13HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | ALDH7A1, BCAT1, BCAT2 | CTSK 2415/4885CTSS 1951/4885HDAC6 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.